Cogent Biosciences, Inc.
General ticker "COGT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.9B (TTM average)
Cogent Biosciences, Inc. follows the US Stock Market performance with the rate: 48.7%.
Estimated limits based on current volatility of 1.9%: low 32.61$, high 33.90$
Factors to consider:
- Total employees count: 258 (+25.9%) as of 2025
- Top business risk factors: Cybersecurity threats, Insufficient funding, Labor/talent shortage/retention, Strategic risks and growth management, Lack of commercialized products
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [15.00$, 42.59$]
- 2026-12-31 to 2027-12-31 estimated range: [8.61$, 25.86$]
Financial Metrics affecting the COGT estimates:
- Negative: with PPE of -18.4 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -15.33 <= -14.17
- Negative: Shareholder equity ratio, % of 67.87 > 64.29
- Negative: Industry earnings per price (median), % of -13.66 <= 0
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
Short-term COGT quotes
Long-term COGT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $208.13MM | $275.94MM | $333.36MM |
| Operating Income | $-208.13MM | $-275.94MM | $-333.36MM |
| Non-Operating Income | $15.72MM | $20.08MM | $4.43MM |
| Interest Expense | $0.00MM | $0.00MM | $3.06MM |
| R&D Expense | $173.75MM | $232.66MM | $269.78MM |
| Income(Loss) | $-192.41MM | $-255.86MM | $-328.94MM |
| Net Income(Loss)* | $-192.41MM | $-255.86MM | $-328.94MM |
| Stockholders Equity | $257.80MM | $256.29MM | $636.37MM |
| Assets | $313.44MM | $327.90MM | $937.61MM |
| Operating Cash Flow | $-153.62MM | $-207.79MM | $-264.44MM |
| Capital expenditure | $2.80MM | $0.57MM | $1.55MM |
| Investing Cash Flow | $-97.82MM | $38.28MM | $-399.53MM |
| Financing Cash Flow | $163.54MM | $214.45MM | $878.23MM |
| Earnings Per Share** | $-2.42 | $-2.46 | $-4.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.